Characterization of Tumor-Suppressive Function of <i>SOX6</i> in Human Esophageal Squamous Cell Carcinoma
-
- Yan-Ru Qin
- Authors' Affiliations: 1Department of Clinical Oncology, the First affiliated hospital, Zhengzhou University, Zhengzhou, China; 2State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou, China; and 3Department of Clinical Oncology, University of Hong Kong, Hong Kong, China
-
- Hong Tang
- Authors' Affiliations: 1Department of Clinical Oncology, the First affiliated hospital, Zhengzhou University, Zhengzhou, China; 2State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou, China; and 3Department of Clinical Oncology, University of Hong Kong, Hong Kong, China
-
- Fajun Xie
- Authors' Affiliations: 1Department of Clinical Oncology, the First affiliated hospital, Zhengzhou University, Zhengzhou, China; 2State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou, China; and 3Department of Clinical Oncology, University of Hong Kong, Hong Kong, China
-
- Haibo Liu
- Authors' Affiliations: 1Department of Clinical Oncology, the First affiliated hospital, Zhengzhou University, Zhengzhou, China; 2State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou, China; and 3Department of Clinical Oncology, University of Hong Kong, Hong Kong, China
-
- Yinghui Zhu
- Authors' Affiliations: 1Department of Clinical Oncology, the First affiliated hospital, Zhengzhou University, Zhengzhou, China; 2State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou, China; and 3Department of Clinical Oncology, University of Hong Kong, Hong Kong, China
-
- Jiaoyu Ai
- Authors' Affiliations: 1Department of Clinical Oncology, the First affiliated hospital, Zhengzhou University, Zhengzhou, China; 2State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou, China; and 3Department of Clinical Oncology, University of Hong Kong, Hong Kong, China
-
- Leilei Chen
- Authors' Affiliations: 1Department of Clinical Oncology, the First affiliated hospital, Zhengzhou University, Zhengzhou, China; 2State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou, China; and 3Department of Clinical Oncology, University of Hong Kong, Hong Kong, China
-
- Yan Li
- Authors' Affiliations: 1Department of Clinical Oncology, the First affiliated hospital, Zhengzhou University, Zhengzhou, China; 2State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou, China; and 3Department of Clinical Oncology, University of Hong Kong, Hong Kong, China
-
- Dora L. Kwong
- Authors' Affiliations: 1Department of Clinical Oncology, the First affiliated hospital, Zhengzhou University, Zhengzhou, China; 2State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou, China; and 3Department of Clinical Oncology, University of Hong Kong, Hong Kong, China
-
- Li Fu
- Authors' Affiliations: 1Department of Clinical Oncology, the First affiliated hospital, Zhengzhou University, Zhengzhou, China; 2State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou, China; and 3Department of Clinical Oncology, University of Hong Kong, Hong Kong, China
-
- Xin-Yuan Guan
- Authors' Affiliations: 1Department of Clinical Oncology, the First affiliated hospital, Zhengzhou University, Zhengzhou, China; 2State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou, China; and 3Department of Clinical Oncology, University of Hong Kong, Hong Kong, China
Description
<jats:title>Abstract</jats:title> <jats:p>Purpose: By using cDNA microarray analysis, we identified a transcriptional factor, SOX6, was frequently downregulated in esophageal squamous cell carcinoma (ESCC). The aim of this study is to investigate the role of SOX6 in human esophageal cancer development, and to examine the prevalence and clinical significance of SOX6 downregulation in ESCC.</jats:p> <jats:p>Experimental Design: Expressions of SOX6 mRNA in 50 ESCCs and SOX6 protein in 300 ESCCs were investigated by semiquantitative RT-PCR and immunohistochemistry, respectively. The tumor-suppressive function of SOX6 was characterized by cell growth, foci formation, wound-healing and cell invasive assays, and tumor xenograft experiment. Western blot analysis was applied to detect protein expression levels.</jats:p> <jats:p>Results: SOX6 was frequently downregulated in primary ESCCs in both mRNA level (29/50, 58%) and protein level (149/219, 68.0%), which was significantly associated with the poor differentiation (P = 0.029), lymph node metastases (P = 0.014), advanced TNM stage (P = 0.000), and disease-specific survival (P < 0.001). Multivariate analysis indicated that the downregulation of SOX6 (P = 0.000) was a significant independent prognostic factors for ESCC. Functional studies showed that SOX6 was able to suppress both in vitro and in vivo tumorigenic ability of ESCC cells. The tumor-suppressive mechanism of SOX6 was associated with its role in G1/S cell-cycle arrest by upregulating expressions of p53 and p21WAF1/CIP1 and downregulating expressions of cyclin D1/CDK4, cyclin A, and β-catenin.</jats:p> <jats:p>Conclusions: We provided the first evidence that SOX6 is a novel tumor-suppressor gene in ESCC development and is a potential prognostic marker in ESCC. Clin Cancer Res; 17(1); 46–55. ©2010 AACR.</jats:p>
Journal
-
- Clinical Cancer Research
-
Clinical Cancer Research 17 (1), 46-55, 2011-01-01
American Association for Cancer Research (AACR)
- Tweet
Details 詳細情報について
-
- CRID
- 1361418519575577088
-
- ISSN
- 15573265
- 10780432
-
- Data Source
-
- Crossref